Clinical Trials on Advanced Uveal Melanoma in New Zealand

Total 1922 results

Lisata Therapeutics, Inc.

Terminated

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

Stage IV Melanoma | Stage III Melanoma

United States
Melanoma Research Foundation Breakthrough Consortium
Genentech, Inc.

Terminated

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Melanoma | Metastatic Melanoma

United States
Immuneering Corporation

Recruiting

A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Pancreatic Adenocarcinoma | Advanced Solid Tumor | Non-small Cell Lung Cancer (NSCLC) | Malignant Melanoma (Cutaneous)

United States
Pfizer

Completed

A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings

Metastatic Melanoma

United States
Delcath Systems Inc.
IQVIA Biotech

Completed

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma (FOCUS)

Melanoma, Ocular

United States, Spain, Italy, Germany, United Kingdom, Switzerland, Belgium, Austria, France
Hoffmann-La Roche

Completed

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Malignant Melanoma

United States, Australia
University of Rochester
National Cancer Institute (NCI)

Completed

Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

United States
Iovance Biotherapeutics, Inc.

No longer available

Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma

United States
CancerVax Corporation

Unknown

Vaccine Therapy in Treating Patients With Malignant Melanoma

Melanoma (Skin)

United States, Australia
Novartis Pharmaceuticals

Recruiting

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma

Spain, Japan, Korea, Republic of, Taiwan, Netherlands, United States, Italy, Canada, Singapore
Bristol-Myers Squibb

Active, not recruiting

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Unresectable or Metastatic Melanoma

United States, France, Poland, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland, United Kingdom, Russian Federation
Hoffmann-La Roche

Completed

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

Malignant Melanoma

United States
Roswell Park Cancer Institute

Recruiting

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery

Sarcoma | Melanoma (Skin)

United States
MedImmune LLC

Completed

Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

Melanoma | Malignant Metastatic Melanoma

United States
Parker Institute for Cancer Immunotherapy
Seres Therapeutics, Inc.

Completed

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW)

Metastatic Melanoma

United States
Clinigen, Inc.
Prometheus Laboratories

Terminated

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma (PROCLIVITY01)

Metastatic Melanoma

United States
Idera Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
University of Alabama at Birmingham
National Cancer Institute (NCI)

Completed

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
Xcovery Holding Company, LLC

Active, not recruiting

Treating Patients With Melanoma and ALK Alterations With Ensartinib

Melanoma

United States
Bristol-Myers Squibb

No longer available

Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma (CheckMate218)

Malignant Melanoma

United States, Canada
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IIIA Skin Melanoma

United States, Australia
Memorial Sloan Kettering Cancer Center
University of British Columbia; San Diego State University; Stony Brook University

Active, not recruiting

Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Schering-Plough

Completed

Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Rockefeller University

Completed

Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Pfizer

Completed

Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma

Melanoma

United States
Dr. Nina Bhardwaj
Cancer Research Institute, New York City

Completed

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Melanoma

United States
Dermatologic Cooperative Oncology Group

Unknown

Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma

Metastatic Melanoma

Germany
Yale University
Apexigen America, Inc.

Recruiting

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma | Advanced Melanoma

United States
Syntrix Biosystems, Inc.
M.D. Anderson Cancer Center; National Cancer Institute (NCI); Massachusetts General... and other collaborators

Recruiting

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Melanoma Stage IV | Melanoma Stage III

United States
Vical

Completed

Phase II Trial of Allovectin-7® for Metastatic Melanoma

Melanoma | Skin Cancer | Metastatic Melanoma | Malignant Melanoma

United States
Philip Friedlander
Genentech, Inc.

Terminated

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Novartis; National Comprehensive Cancer Network

Completed

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Melanoma

United States
NYU Langone Health

Terminated

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

Melanoma

United States
Genta Incorporated

Unknown

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Array BioPharma

Completed

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Melanoma

United States
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
National Cancer Institute (NCI)

Completed

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Canadian Cancer Trials Group
Melanoma and Skin Cancer Trials Limited

Recruiting

Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

Unresectable/Metastatic Melanoma

Canada, Australia
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B; SWOG Cancer Research...

Completed

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Bristol-Myers Squibb

Completed

Long-term Data Collection for Subjects in MDX-010 Studies (MDX010-28)

Metastatic Melanoma

United States
Melanoma and Skin Cancer Trials Limited
Norfolk and Norwich University Hospitals NHS Foundation Trust; Canadian Cancer... and other collaborators

Recruiting

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (MelMarT-II)

Cutaneous Melanoma, Stage II

United States, Canada, United Kingdom, Australia, Italy, Sweden, Netherlands, New Zealand
Hoffmann-La Roche

Terminated

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Malignant Melanoma

United States, France, Australia, United Kingdom, Italy, Spain, Germany, Israel, Poland, Slovakia
Bristol-Myers Squibb

Withdrawn

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Melanoma

United States
Viralytics

Completed

Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) (CAPRA)

Melanoma

United States
Infinity Pharmaceuticals, Inc.

Terminated

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Bristol-Myers Squibb

Completed

Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States

Melanoma

United States
AmpliMed Corporation

Completed

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

Malignant Melanoma

United States
Hoffmann-La Roche

Completed

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma (coBRIM)

Malignant Melanoma

United States, Spain, Hungary, Israel, United Kingdom, Australia, Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, Russian Federation, Sweden, Switzerland, Canada, New Zealand, Norway

Clinical Trials on Advanced Uveal Melanoma in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations